Skip to content

CO2 Modulation in Endovascular Thrombectomy for Acute Ischemic Stroke

Evaluation of the Effect of Moderate and Controlled Hypercapnia on Ischemic Penumbra Vascular Collaterality During General Anesthesia for Anterior Circulation Acute Ischemic Stroke Mechanical Thrombectomy

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05051397
Acronym
COMET-AIS
Enrollment
50
Registered
2021-09-21
Start date
2022-07-20
Completion date
2028-10-20
Last updated
2026-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, General, Carbon Dioxide, Cerebrovascular Circulation, Ischemic Stroke, Acute, Thrombectomy

Keywords

mechanical thrombectomy, large vessel occlusion stroke, carbon dioxide tension, cerebral blood flow, general anesthesia, cerebral collateral circulation

Brief summary

Acute ischemic stroke due to large vessel occlusion is responsible of cerebral blood flow impairment with a progressive and extensive ischemic process. Cerebral collateral circulation may preserve an ischemic penumbra that could recover providing timely reperfusion of the occluded vessel. Mechanical thrombectomy is the standard of care for anterior circulation large vessel reperfusion. Strategy to promote cerebral blood flow in collateral circulation before reperfusion is scarce and rely mainly on blood pressure maintenance. Carbon dioxide is a potent cerebral vasodilator that could enhance collateral circulation blood flow and cerebral protection before reperfusion. General anesthesia with endotracheal mechanical ventilation could be used for thrombectomy and give the opportunity to modulate and control carbon dioxide tension in the blood. This study will test the effect of moderate hypercapnia on penumbral collateral circulation before reperfusion during mechanical thrombectomy for anterior circulation acute ischemic stroke under general anesthesia.

Detailed description

Study will compare 2 groups of patients treated for anterior circulation large vessel occlusion stroke thrombectomy under general anesthesia. After anesthetic evaluation, patients will be randomized to receive moderate hypercapnia targeting an arterial CO2 tension (PaCO2) of 50mmHg or normocapnia targeting a PaCO2 of 40mmHg. The anesthetic protocol will use: * Rapid sequence induction for orotracheal intubation with PROPOFOL 2mg/Kg and SUXAMETHONIUM 1mg/Kg * SUFENTANIL 0,1 µg/Kg and CISATRACURIUM 0,1mg/Kg * Maintenance with intravenous continuous infusion of PROPOFOL targeting a BISpectral index 40 to 60 * Systolic blood pressure will have to be maintained +/- 10% of preoperative baseline value with limits between 120 and 185mmHg (with NOREPINEPHRINE as needed) * Mechanical ventilation will use Tidal Volume of 7mL/Kg of ideal body weight, respiratory rate of 15/minute, End expiratory pressure of 5cmH2O. FiO2 will target SpO2 95-98%. Initial End Tidal CO2 (EtCO2) target will be 35mmHg. * A first arterial blood gas analysis at groin puncture will evaluate CO2 alveolar-arterial gradient in order to obtain the expected PaCO2 in each group with respiratory rate modulation on the ventilator. * ASITN baseline collaterality score will be evaluated at initial angiography with normocapnia in each group. A second evaluation of ASITN will be done just before deployment of intraarterial revascularisation device in hypercapnia or normocapnia depending on randomisation group. * Targeted PaCO2 will have to be maintained using EtCO2 surrogate until the end of procedure. * A second arterial blood gas analysis at the end of procedure will evaluate final PaCO2.

Interventions

BIOLOGICALHYPERCAPNIA

Controlled moderate hypercapnia PaCO2 50mmHg under general anesthesia with mechanical ventilation

BIOLOGICALNORMOCAPNIA

Controlled normocapnia PaCO2 40mmHg under general anesthesia with mechanical ventilation

Sponsors

University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

• Large vessel occlusion anterior circulation stroke (terminal carotid artery and/or middle cerebral artery M1-M2 segment) eligible to mechanical thrombectomy under general anesthesia

Exclusion criteria

: * Active smoker * Chronic respiratory failure with ambulatory oxygen supplementation * Obesity with BMI\>40Kg/ m2 * Intubation before the procedure * Heart failure with intolerance to decubitus * Severe renal failure * Suspected elevated intracranial pressure * Pregnant or breastfeeding women

Design outcomes

Primary

MeasureTime frameDescription
ASITN cerebral vascular collaterality score > 2Before reperfusion of the occluded vesselAmerican Society of Interventional and Therapeutic Neuroradiology (ASITN) cerebral vascular collaterality score ranges from 0 (no collaterals visible to the ischemic site) to 4 (complete and rapid collateral blood flow to the vascular bed in the entire ischemic territory by retrograde perfusion). A score \> 2 indicate at least collaterals with slow but complete angiographic blood flow of the ischemic bed by the late venous phase.

Secondary

MeasureTime frameDescription
ASITN cerebral vascular collaterality score• At initial angiography in normocapnia and • Before reperfusion at randomized arterial CO2 tension levelAmerican Society of Interventional and Therapeutic Neuroradiology (ASITN) variation during the procedure
Volume of cerebral infarction24 hours after strokeEvaluated with Magnetic Resonance Imaging in milliliters
Progression of cerebral infarction24 hours after strokeEvaluated with Magnetic Resonance Imaging or Computed Tomography in milliliters depending on type of radiological modality for patient selection
Neurological clinical outcome3 monthsOrdinal and dichotomized modified rankin scale (mRS) ranging from 0 (no disability) to 6 (death); good outcome will be defined as mRS 0-2.

Countries

France

Contacts

CONTACTLise Laclautre
promo_interne_drci@chu-clermontferrand.fr+33 4 73 754963
PRINCIPAL_INVESTIGATORRussell Chabanne, MD MSc

University Hospital, Clermont-Ferrand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 4, 2026